Related Experiment Video
Updated: Jun 14, 2025
Investigations on the GaIII Complex of EOB-DTPA and Its 68Ga Radiolabeled Analogue
Published on: August 17, 2016
Bisphosphonate Bone Imaging Agent [68Ga]Ga-P15-041 for Evaluating Skeletal Metastases in Prostate Cancer: A
Jiarou Wang1,2,3, Linlin Li1,2,3, Tianrui Feng4
1Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College.
Background:
Accurate diagnosis of bone metastases in prostate cancer is essential for staging, prognosis, and treatment. Although PSMA PET/CT is highly effective, complementary imaging is needed to clarify indeterminate lesions. The novel bisphosphonate-based agent [68Ga]Ga-P15-041 shows superior diagnostic accuracy over conventional SPECT imaging, indicating its potential as an auxiliary diagnostic tool. This study explores its role in detecting and assessing prostate cancer bone metastases.
Patients And Methods:
This prospective study enrolled 35 patients with prostate cancer and skeletal metastases, who underwent both [68Ga]Ga-P15-041 and [68Ga]Ga-PSMA-11 PET/CT within 1 week. Lesions detected by [68Ga]Ga-PSMA-11 PET/CT were classified using Prostate-specific Membrane Antigen Reporting and Data System 2.0.
Results:
[68Ga]Ga-P15-041 PET/CT detected more lesions than [68Ga]Ga-PSMA-11 PET/CT (525 vs 509, P < 0.001) and demonstrated significantly higher tracer uptake, with a mean SUV of 20.73 ± 14.67 compared with 11.13 ± 8.12 (P < 0.0001). It detected significantly more osteoblastic lesions (504 vs 391, P < 0.0001). In addition, this study established the Reporting and Data System for [68Ga]Ga-P15-041 (P15-041-RADS), which classifies prostate cancer bone metastases into 5 categories based on SUVmax and morphologic changes. P15-041-RADS reclassified 85.71% of Prostate-specific Membrane Antigen Reporting and Data System category 3 lesions and 95.00% of 5T lesions into higher-confidence categories, offering improved diagnostic clarity. Limitations include small sample size and lack of pathologic gold standards.
Conclusions:
[68Ga]Ga-P15-041 PET/CT is a promising and accessible bone imaging agent that could complement [68Ga]Ga-PSMA-11 PET/CT in the diagnosis and classification of bone metastases in prostate cancer.
More Related Videos
09:06Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
Published on: February 3, 2023
08:55A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
Related Concept Videos
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
01:29Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
01:13Radiological Investigation III: Pulmonary Angiogram and PET Scan
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...